Introduction {#S1}
============

Loss of insulin-producing pancreatic β-cells ultimately characterize most diabetic conditions, prompting extensive efforts aimed at replenishing these cells from either endogenous ([@B10]; [@B56]) or exogenous sources ([@B2]). As part of the latter strategies, the employment of human induced pluripotent stem cells (hiPSC) as a source for insulin-producing cells has gained a lot of momentum in the recent years ([@B29]; [@B34]). These methods are based on a stepwise hiPSC differentiation strategy mirroring the stages characterizing β-cells fate acquisition during development ([@B35]; [@B30]; [@B38]).

Despite generating insulin-producing cells with varying degrees of functional maturity, most current protocols present heterogeneous outputs, also producing cells secreting other pancreatic islet hormones ([@B37]; [@B47]). Moreover, some of the differentiating cells presents a hybrid phenotype, expressing more than one hormone ([@B8]; [@B37]; [@B47]). This is in stark contrast to the *bona fide* human islet cells, which in homeostatic conditions are restricted to secrete a single pancreatic hormone: glucagon (α-cells), insulin (β-cells), somatostatin (δ-cells), pancreatic polypeptide (PP/γ-cells) or ghrelin (ε-cells) ([@B21]; [@B14]). The ambiguous hormone selection presented by the cells differentiated *in vitro* represents an important problem ([@B27]), as this is usually connected with functional immaturity. Consequently, many differentiation protocols were aimed at improving the monohormonal cell fractions. Recent studies ([@B32]; [@B46]) report novel embryonic stem cells (ESC) differentiation strategies leading to substantial improvements of β-cell maturation and functionality. Indeed, these ESC-derived β-cells presented an energy metabolism fingerprint and glucose stimulated insulin secretion similar to the one observed in human islets.

In addition, xeno-transplantation into living hosts, such as mice, has been shown to significantly increase the yield and functionality of the differentiating hPS-derived cells ([@B26]; [@B40], [@B39]; [@B36]). Indeed, after extensive periods of time (2--6 months), the xenotransplantation of circa two million *in vitro* differentiated cells was able to normalize the glycemia in diabetic mice ([@B36]; [@B39]; [@B1]; [@B45]; [@B6]; [@B42]). Although these experiments highlighted the importance of the *in vivo* environment and its systemic factors in promoting islet cell fate, the signals governing this process are largely unknown. Moreover, the graft response to the *in vivo* environment was not yet properly characterized.

In this study we aimed to address this knowledge gap by demultiplexing and characterizing the initial response of the hiPSC-derived differentiating pancreatic progenitors to the *in vivo* environment, using global proteomics and large-scale imaging techniques. Here we show that the *in vivo* exposure rapidly routes a large fraction of human pancreatic progenitors toward single hormone expression. Moreover, the overall proteome landscape of the transplanted cells was closer to a native islet-like regulation pattern and especially the energy metabolism and redox signature. Our study suggests a potential link between these, and the improvement of hormone selection through regulation of epigenetic factors involved in maintaining and propagating the patterns of hormone expression. Last, we identified by pathway analysis two upstream regulators, HNF1A and HNF4A predicted to be responsible for the *in vivo* islet promoting response of the transplanted cells and experimentally confirmed their role in confining human pancreatic progenitors to single hormone expression.

Materials and Methods {#S2}
=====================

Cell Sources and Ethics Statements {#S2.SS1}
----------------------------------

The Norwegian Regional Committee of Medical and Health Research Ethics approved the reported experimental protocols used for hiPSCs (REK 2010/2295) and for human islets (REK 2011/426). All methods were carried out in accordance with the Helsinki Declaration. Informed consent was obtained from the healthy and MODY1/3 patient donors (skin fibroblasts) or from the relatives (organ donations). The human induced pluripotent stem cells (hiPSCs) used in this paper were generated using episomal reprograming with vectors from Addgene \#27077 (OCT3/4), \#27080 (L-MYC, LIN28) and \#27078 (SOX2, KLF4) as previously described by us ([@B47]; [@B5]). Proteomic analyses of *HNF1*α^Δ/+^ was performed on cell lines generated by Sendai reprograming carried out by Tekara Bio Inc., using a CytoTune-iPS 2.0 Sendai reprogramming kit (\#A16517, Life Technologies) as described in [@B5]. All hiPSC lines were negative for mycoplasma, by using MycoAlert Mycoplasm Detection Kit (Lonza, LT07-418). Seven distinct iPSC lines were used in the study. The pluripotency of the iPSC lines was previously tested ([@B47]; [@B5]), while their differentiation potential was previously assessed in [@B47], [@B28], [@B48]. Human islets were obtained as previously described ([@B19]) from seven deceased donors (males and females).

Cell Preparation {#S2.SS2}
----------------

The hiPSC lines were enriched for SSEA4^+^ cells using magnetic beads (\#130097855 MACS Miltenyi Biotec) before *in vitro* differentiation. Both normal and mutated hiPSCs were differentiated according to a seven-stage protocol ([@B39]). The planar differentiation efficiencies estimated as insulin^+^ NKX6.1^+^ co-expressing cells were similar with the previously reported values ([Supplementary Figure S1A](#SM1){ref-type="supplementary-material"}). Also, this percentage was similar between WT and HNF1A^Δ/+^ in two independent differentiation rounds ([Supplementary Figure S2L](#SM1){ref-type="supplementary-material"}). The differentiation efficiencies for HNF4A^Δ/+^ clones was previously assessed in [@B47] and consequently assumed similar in this work. For this study we used 2D differentiation on Matrigel-coated plates until Stage 5 (S5; pancreatic endocrine precursors), or up to Stage 7 (S7; maturing beta-cells), S5 cells were encapsulated in alginate before continued differentiation toward S7, and S5 and S7 cells encapsulated in alginate prior to *in vivo* transplantation. Alginate encapsulation was performed as we have described earlier ([@B49]). Cell number and viability was measured as previously described ([@B49]). Cell viability mean was 86.53 ± 7.03%. The fraction of dying cells at different time points following transplantation in normoglycemic animals was similar to the previously reported ([@B28]) and was estimated at ∼7.5% between 1- and 4-weeks postTX.

Flow Cytometry Analysis {#S2.SS3}
-----------------------

Differentiating cells from stage 5 (pancreatic endocrine precursors) or stage 7 (maturing beta cells), were collected using TrypleTM Select Enzyme (1X). Cells were first checked for viability using NucleoCounter^®^ NC-200^TM^ (Dąbrowskiego, Poznań, Poland), and only more than 80% viable cells were used in the assay. Cells were washed and incubated in a 96-well plate (v-bottom, 2 × 105 cells per well) with Fixation/Permeabilization solution 20 min. After washing with Perm/Wash Buffer, cells were stained for 45 min in the dark at RT with FITC-conjugated anti-insulin and AF647-conjugated anti-NKX6.1. Markers were set according to the isotype control FITC or AF647-conjugated mouse IgG1. After washing in PBS, the cells were examined on a flow cytometer (BD LSRFortessa, Becton-Dickinson Biosciences, San Jose, CA, United States). Gating was performed according to the isotype control. FACS analysis was done using FlowJo (Flow cytometry analysis software, Ashland, OR, United States).

Transplantation {#S2.SS4}
---------------

For transplantation we used the following transgenic mouse line NOD.*Cg-Prkdc^*scid*^Il2rg^*tm1Wjl*^* Tg (Ins2-HBEGF) 6832Ugfm/Sz ([@B55]) referred to as NSG RIP-DTR. Three mice (8--12 weeks old) were used for each group. The mice for the diabetic group received diphtheria toxin injections intraperitoneal (ip) as previously described ([@B44]; [@B11]). Glycemia were measured two times per week with a Contour XT glucometer (Bayer). The mice received transplantation of alginate beads intraperitoneally when anesthetized with inhalable sevoflurane administered via Datex-Ohmeda Sevotec 5. Each mouse was transplanted with approximately five million cells. Transplanted mice received 0.5 mg/ml paracetamol in the drinking water for 5 days post-transplant. At the end of *in vivo* incubation of the transplanted cells, mice were euthanized by cervical dislocation and the alginate beads were collected from the intraperitoneal cavity by lavage. Beads were rapidly washed in saline solution for removing traces of blood and host tissue and either immediately fixed in 4% PFA or transferred in lysis buffer for proteomics. All animal procedures were performed in accordance with the EU Directive 2010/63/EU for animal experiments. The breeding strategy and experimental protocols were approved by the Norwegian Animal Research Authority (FOTS IDs 8329 and 8423). The mice were housed in individually ventilated cages (IVC) enriched with wooden bedding, nesting material, in a temperature-controlled environment at 22°C under a 12-h light-dark cycle. The mice were given *ad libitum* access to water and standard diet RM1A (SDS).

Immunofluorescence {#S2.SS5}
------------------

Preparation and immunofluorescence of alginate beads were performed as previously described ([@B49]). The pancreas from the mice were fixed for 2 h in 4% PFA, before dehydration using a sucrose gradient of 10, 20, and 30% and embedded in Tissue Tek OCT compound (Sakura JP). Sections of 10 μm were obtained with a cryotome (Leica CM 1950, Leica, DE) and added on SuperFrost Plus slides (Thermo Scientific). The immunofluorescence staining was performed following indications provided by the supplier. The following primary antibodies were used: mouse anti-insulin IgG1 (1/500, I2018, Sigma-Aldrich), guinea-pig anti-porcine insulin (1/400, A056401-2, Dako), mouse anti-porcine glucagon (1/1000, G2654, Sigma-Aldrich). The following secondary antibodies were used at dilution 1/500: goat anti-mouse IgG1 A488, goat anti-guinea-pig A488, goat anti-guinea-pig A546, goat anti-mouse IgG1 A546. DAPI (1/1000, D1306, Molecular Probes) was used to stain the nuclei. The samples were mounted in Prolong Diamond Antifade Mountant Media (P36970, Life technologies). Image acquisition and analysis was performed on Andor Dragonfly confocal microscope and Imaris 9.1.2 (Bitplane AG) as we have previously described ([@B49]). We also performed manual counting on images acquired using a 40x immersion objective on Leica TCS SP5 confocal (Leica Microsystems CMS GmbH).

Global Proteomics Analysis {#S2.SS6}
--------------------------

The proteomics analysis for the *in vitro* samples and associated human islets were performed as we have earlier described ([@B49]) dataset identifier PXD012704, with the exception of the *HNF1*α^Δ/+^ samples which were performed as in [@B47]. Protein samples from the *in vivo* transplanted cells were processed for Tandem Mass Tag (TMT) 11-plex as for the *in vitro* samples, apart from the use of halved volume of TMT reagents. A total of 12 fractions were collected from the pooled TMT-labeled peptide samples using the Pierce High pH Reversed-Phase Peptide Fractionation Kit (cat. \# 84868) and 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, and 60% acetonitrile. Every sixth of these fractions were combined to yield six fractions in total. Subsequently we acidified the samples using 1% formic acid before vacuum centrifuged to near dryness. Each fraction was desalted using StageTip, dried via vacuum centrifugation, and reconstituted for LC-MS/MS processing. For LC-MS3 analysis ∼5 μg from each fraction was dissolved in 15% aqueous formic acid/5% acetonitrile prior to loading on an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific, San Jose, CA, United States) coupled to a Proxeon EASY-nLC 1200 liquid chromatography (LC) pump (Thermo Fisher Scientific). By using a 100-μm inner diameter microcapillary column packed with ∼35 cm of Accucore resin (2.6 μm, 150 Å, ThermoFisher Scientific) the peptides were fractionated. We loaded ∼1 μg onto the column for each analysis. Subsequent separation and acquisition were performed as previously described ([@B49]). Samples were analyzed in duplicate, one with advanced peak determination (ADP) activated and a second run with this option off. Both analyses used the real-time search (RTS) algorithm ([@B16]). Data was searched against the UniProt human database (downloaded: October, 2016). The dataset was uploaded to ProteomeXchange via the PRIDE^[1](#footnote1){ref-type="fn"}^ partner repository with the dataset identifier PXD015955. The hyperglycemia samples from this dataset were not analyzed in this work. Two human islets samples were excluded from analysis due to islet quality problems.

Proteomic Data Analysis {#S2.SS7}
-----------------------

We analyzed the mass spectrometry data as earlier described ([@B49]). Protein quantify values were analyzed using Microsoft Excel and GraphPad Prism (version 8). Hierarchical clustering was performed using with GeneSpring 14.9.1 GX software (Agilent), with clustering on both entities and conditions by using Squared Euclidian distance metric and Ward's linkage rule. The pathway analyses were generated by QIAGEN's Ingenuity Pathway Analysis program (IPA^®^, QIAGEN, Redwood City, United States)^[2](#footnote2){ref-type="fn"}^ ([@B25]) as previously described ([@B49]), here using 35 molecules/network; 25 networks/analysis for generating the interaction networks.

Statistical Analysis {#S2.SS8}
--------------------

For the immunofluorescence counting we used Mann-Whitney non-parametric test to compare the number of hormonal cells between the different groups using GraphPad Prism v8.1.2. Also, unpaired two-tailed Student's *t*-tests were used for analyzing the proteomics data. A *p*-value of \<0.05 was considered significant.

Results {#S3}
=======

Short-Term Exposure of Encapsulated Pancreas Progenitor Cells to *in vivo* Environment Promotes an Islet-Like Signature {#S3.SS1}
-----------------------------------------------------------------------------------------------------------------------

To investigate the short-term effect of the *in vivo* environment on islet cell differentiation, we xenotransplanted encapsulated hiPSC-derived pancreas progenitors (from here on S5-cells) into the intraperitoneal cavity of humanized NSG mice ([Supplementary Figure S1B](#SM1){ref-type="supplementary-material"}). Based on its consistent reproducibility and popularity, we employed an established protocol ([@B39]) for the initial directed differentiation (*in vitro*). The resulting S5-cells (five million cells) were encapsulated in alginate and then immediately transplanted into normoglycemic mice for 2 weeks (*in vivo*), a period of time equivalent to the one required for generating maturing islet cells *in vitro* (2 weeks).

As the mechanical forces elicited by the encapsulation of cells can in itself interact with the differentiation response to the differentiation cocktails ([@B49]), we used an array of experimental conditions aimed to ultimately demultiplex the *in vivo*-specific molecular mechanisms stimulating the islet cell fate acquisition program ([Figure 1A](#F1){ref-type="fig"}). As such, pancreas progenitors (S5-cells) were differentiated toward islet cell fates (1) *in vitro* on Matrigel-coated plates (planar 2D culture condition; termed "S7-cells"), (2) *in vitro* in alginate capsules (termed "S7^enc\[S5--S7\]^″) and (3) *in vivo* following xenotransplantation (termed "2w_postTX"). In this setup, the comparative analysis of the molecular signatures exhibited by the resulted end-stage cellular entities grants the possibility of discriminating between the effects of the (i) differentiation cocktail, (ii) encapsulation, (iii) *in vivo* environment.

![Assessment of the pancreatic islet hormones expression by global proteomics and large-scale imaging following three distinct differentiation strategies **(A)** Experimental design depicting the three differentiation strategies considered. Numbers in bold represent differentially expressed proteins (DEPs) between the final differentiation stage (S7, S7^enc\[S5--S7\]^, 2w_postTX) and pancreatic progenitors (S5), following islet-standard normalization (data represent two distinct TMT-11 plexes). **(B)** Graphs displaying the statistically significant (FC ≥ 1.5, *p* \< 0.05) regulated islet hormones (colored bars) identified in the DEPs set characterizing each differentiation strategy (*in vitro* Matrigel differentiation -- chartreuse, *in vitro* encapsulation -- yellow and *in vivo* transplantation of encapsulated cells -- light green). **(C)** 3D reconstructions of dragonfly imaged whole alginate capsules containing cells immunofluorescently labeled for insulin (green), glucagon (red) and DAPI (blue) in the four conditions analyzed (scale bar 200 μm, gamma correction 0.4). **(D)** Proportion of monohormonal glucagon cells in the four distinct populations analyzed (*n* = 9,18,18,18) and the high magnification of a representative encapsulated glucagon^+^ cell. **(E)** Proportion of monohormonal insulin in the four distinct populations analyzed (*n* = 9,18,18,18) and the high magnification of a representative encapsulated insulin^+^ cell. **(F)** Proportion of bihormonal cells (insulin^+^glucagon^+^ co-expressing) and a high magnification of a representative encapsulated bihormonal cell. High magnification scale bars: 5 μm. Graphs data are shown as box plot mean to max values. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 (Mann--Whitney test). Abbreviations: TX, transplant; 2D, Matrigel differentiation; 3D, alginate encapsulation; DEPs, differentially expressed proteins; Dt, time interval; FC, fold change; S5-cells, stage 5 cells (pancreatic progenitor stage); S7-cells, stage 7 cells (maturing β-cells); S7^enc\[S5--S7\]^, differentiated in capsules from stage 5 to stage 7; 2w_postTX, 2 weeks following transplantation (differentiation in mice).](fcell-08-00109-g001){#F1}

We first performed global proteomics on the S5 cells, their respective differentiation counterparts (S7, S7^enc\[S5--S7\]^, 2w_postTX cells) and human islets isolated from cadaveric donors. 2369 proteins were detected in all conditions across TMT-plexes ([Supplementary Figure S1C](#SM1){ref-type="supplementary-material"}). About two thirds (64.83%, 1536/2369) represented differentially expressed proteins (DEPs) between the S5-cells (pancreatic progenitors) and the directed differentiation goal, the bona fide human islet cells (FC ≥ 1.5, *p* \< 0.05). The principal component analysis (PCA) revealed a clear separation of the samples according to the differentiation strategy (Principal Condition 1: 40.48%). The 2w_postTX cluster of samples exhibited the highest similarity with human islets ([Supplementary Figure S1D](#SM1){ref-type="supplementary-material"}, green). The hierarchical clustering confirmed these results, as the recovered xenotransplanted cells branched closer to human islets ([Supplementary Figure S1E](#SM1){ref-type="supplementary-material"}). Furthermore, a direct comparison of these sets revealed that 14.78% (227/1536) proteins were differentially expressed between transplanted cells and islets. These results indicate that a relevant number of proteins changed their pattern of expression toward an islet-like signature even after just a brief exposure to the *in vivo* environment.

Short-Term Exposure to *in vivo* Environment Increases the Abundance of the Main Islet Hormones {#S3.SS2}
-----------------------------------------------------------------------------------------------

Based on their islet-normalized profile, 738, 1110 and respectively, 1055 proteins exhibited a significant change of their regulatory dynamic (FC ≥ 1.5, *p* \< 0.05) in response to the distinct differentiation conditions described above ([Figure 1A](#F1){ref-type="fig"}, [Supplementary Figure S1F](#SM1){ref-type="supplementary-material"}, and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). Among the 1055 DEPs regulated following 2 weeks of transplantation, the main islet-specific hormones, insulin, glucagon and somatostatin were significantly upregulated, with glucagon displaying the highest increase ([Figure 1B](#F1){ref-type="fig"}). Interestingly, glucagon expression was promoted by all differentiation conditions, while insulin and somatostatin were promoted only by the 3D settings (*in vitro* and *in vivo* encapsulated conditions). In contrast, the pancreatic polypeptide, a hormone produced by the pancreatic PP/γ-cells, was not promoted in the transplanted samples, being significantly regulated solely in the *in vitro* differentiating capsules (S7^enc\[S5--S7\]^). Last, the pan-endocrine marker Chromogranin A (CHGA), which exhibited increased abundance in the *in vitro* setups, was not significantly regulated *in vivo* ([Figure 1B](#F1){ref-type="fig"}).

These data suggest that even short exposure of S5 cells to the *in vivo* environment is enough to increase the expression of the three main islet hormones, including insulin. Nevertheless, it is not sufficient for induction of pan-endocrine markers such as CHGA. This indicates that the brief exposure to the *in vivo* environment promotes hormone production in the differentiating cells, but is probably insufficient for recruiting new progenitors toward the endocrine program.

Short-Term Exposure to *in vivo* Environment Does Not Increase the Hormone Positive Fraction but Improves Their Monohormonal Identity {#S3.SS3}
-------------------------------------------------------------------------------------------------------------------------------------

To discriminate if the brief *in vivo* exposure increases the fraction of hormone positive cells as opposed to improving the hormone production in the transplanted encapsulated cells, we performed large scale imaging microscopy of the three differentiation conditions. To allow the use of similar counting algorithms, a similar number of the cells differentiated in the planar 2D setup (S7-cells) were fixed and encapsulated just before image acquisition ([Figure 1C](#F1){ref-type="fig"}). Briefly, for each capsule a mosaic of nine fields of view (FoV) over 100 *z*-planes were acquired, reconstructed and automatically quantified by using Imaris 9.1.2 as previously described by us ([@B49]). The quantification revealed the rise of the monohormonal glucagon^+^ ([Figure 1D](#F1){ref-type="fig"}) and insulin^+^ ([Figure 1E](#F1){ref-type="fig"}) fraction in the encapsulated cells following brief exposure to the *in vivo* environment (compare 2w_postTX and S5 columns). Moreover, this was coupled with a significant decrease in the proportion of immature bihormonal cells ([Figure 1F](#F1){ref-type="fig"}). Overall, these results corroborate that rather than increasing the number of hormone expressing cells, the *in vivo* transplantation enhances the quality of the differentiated encapsulated cells. This is probably achieved by refining the accuracy of cell fate/hormone status selection and improving hormone production.

The Demultiplexed *in vivo* Effect Promotes Oxidative Phosphorylation and Neuritogenesis {#S3.SS4}
----------------------------------------------------------------------------------------

Further, to globally characterize the response to the *in vivo* environment besides islet hormone regulation, we first discriminated the *in vivo* effect signature and subsequently performed pathway analysis.

As the S5-cells are encapsulated before transplantation to protect against the immune attack as well as to allow their retrieval, the above results reflect the combinatorial impact of both alginate encapsulation and *in vivo* environment. To focus exclusively on the latter (*in vivo* effect), the readout of the three differentiation setups was used to accurately exclude the encapsulation effect. First, to comprehensively define the protein set significantly regulated by encapsulation, we compared the two *in vitro* conditions, i.e. standard differentiation (differentiation cocktail effect) and cells differentiating in capsules (differentiation cocktail and encapsulation effect) ([Figure 2A](#F2){ref-type="fig"}). The Venn comparison revealed 582 DEPs being modulated exclusively as a result of the encapsulation effect. Moreover, although 528 DEPs were found regulated by both conditions, about three quarters (76.70%, 405/528 DEPs) displayed distinct regulatory patterns according to the differentiation setup (FC ≥ 1.5 of difference). This indicates that despite being mainly targets of the differentiation cocktail, their regulation is also significantly influenced by encapsulation and thus likewise a consequence of this effect. Subsequently, the overall encapsulation effect signature was compared against the *in vivo* differentiation setup. The Venn diagram filtered 307 DEPs regulated solely by the *in vivo* effect, while 489 shared a common, however, differential, regulation of the encapsulation and *in vivo* effects ([Figure 2A](#F2){ref-type="fig"} and [Supplementary Table S2](#TS2){ref-type="supplementary-material"}).

![Pathway analysis of the proteome landscape following *in vivo* exposure. **(A)** Analysis workflow depicting the strategy used for demultiplexing the *in vivo* effect **(B)** IPA-generated top canonical pathways with predicted regulation (*z*-score ≥ 1.1) characterizing the *in vivo* response. **(C)** Top predicted activated upstream transcription regulators and the HNF1A target molecules observed regulated in the *in vivo* effect DEPs dataset. **(D,E)** IPA-generated networks and graph representations of selected dataset DEPs characterizing the corresponding top disease and function processes. Abbreviations: TX, transplant; DEPs, differentially expressed proteins; FC, fold change; S5-cells, stage 5 cells (pancreatic progenitor stage); S7-cells, stage 7 cells (maturing β-cells); S7^enc\[S5--S7\]^, differentiated in capsules from stage 5 to stage 7; 2w_postTX, 2 weeks following transplantation (differentiation in mice), Path, pathway. For abbreviations see [Supplementary Table S3](#TS3){ref-type="supplementary-material"}.](fcell-08-00109-g002){#F2}

To identify the protein networks, signaling pathways and upstream regulators characterizing the overall *in vivo* environment signature, we performed pathway analysis on the resulted *in vivo* effect protein set ([Supplementary Table S2](#TS2){ref-type="supplementary-material"}). The Ingenuity Pathway Analysis (IPA) software revealed a strong energy metabolism ([Supplementary Figure S2A](#SM1){ref-type="supplementary-material"}), with pathways such as oxidative phosphorylation (OXPHOS) being confidently predicted as activated following transplantation ([Figure 2B](#F2){ref-type="fig"}). This is suggestive of the impact of transplantation on the redox balance of the differentiating cells. Furthermore, the analysis identified the Hepatocyte nuclear factor 1-alpha (HNF1A) transcription factor as the leading activated upstream regulator responsible for the observed regulatory landscape ([Supplementary Figure S2B](#SM1){ref-type="supplementary-material"}). Of note, in the top activated transcriptional regulators the program inferred the involvement of transcription factors involved in the pancreatic islet development (Hepatocyte nuclear Factor 4A -- HNF4A and Pancreas transcription factor 1A -- PTF1A), as well as cellular senescence and growth (Cyclin-dependent kinase inhibitor 2A -- CDKN2A and Forkhead box protein O3 - FOXO3), suggesting the role of the *in vivo* niche on islet cell fate decision, consistent with the above observations ([Figure 2C](#F2){ref-type="fig"} and [Supplementary Figure S2C](#SM1){ref-type="supplementary-material"}).

Interestingly, the disease and function analysis pinpointed with high confidence the decrease of both synthesis and production of active oxygen species ([Figure 2D](#F2){ref-type="fig"} and [Supplementary Figure S2D](#SM1){ref-type="supplementary-material"}), which combined with the observed increase of OXPHOS and low antioxidant activity ([Figure 2B](#F2){ref-type="fig"}), advocate a scenario consistent with an improvement of the energy metabolism of the differentiating cells following transplantation and not a tilt of the redox balance toward oxidative stress.

Aside from the energy metabolism signature, the analysis predicted a decrease in the cholesterol metabolism and an activation of vitamin metabolism in the transplanted cells ([Supplementary Figure S2D](#SM1){ref-type="supplementary-material"}). Moreover, a robust activation of a neurogenesis/neuritogenesis signature was supported by a large fraction of the data set ([Figure 2E](#F2){ref-type="fig"} and [Supplementary Figure S2E](#SM1){ref-type="supplementary-material"}), which combined with the short transplantation period argue in favor of the transplanted differentiating cells (graft) stimulating the innervation from the niche. This is similar to islet cells transplanted underneath the kidney capsule, known to promote the innervation of the graft in the first weeks following transplantation ([@B24]; [@B43]).

The *in vivo* Environment Shifts the Energy Metabolism Signature of the Transplanted Cells Toward Native Islet Regulation {#S3.SS5}
-------------------------------------------------------------------------------------------------------------------------

To assess if the observed proteome landscape changes induced by the *in vivo* effect lead to an improved islet-like signature, we focused on differentially expressed proteins that following *in vivo* exposure are regulated toward the abundance levels normally detected in native islets ([Figure 3A](#F3){ref-type="fig"}). About half of the proteins encompassed by the *in vivo* effect (56.53% 450/796, [Supplementary Table S2](#TS2){ref-type="supplementary-material"}) presented an islet-promoting regulation, with ∼22.23% (177/796) reaching islet abundance values. Most (63.11% 284/450) were upregulated, i.e. characterized by low abundance in S5-cells, as compared to islets followed by an increase toward islet abundance levels following transplantation ([Figure 3A](#F3){ref-type="fig"}, lower quadrant).

![Pathway analysis of proteins following islet-promoting regulation patterns as result of the *in vivo* effect. **(A)** Scheme depicting the selection strategy and waffle charts reflecting the number of proteins showing a dynamic of regulations compatible with an islet-promoting pattern in response to the *in vivo* effect. The scheme circles reflect the regulation reported to the islet abundance levels. Arrows represent the generic mandatory direction of regulation for inclusion in the islet-promoting signature (blue -- downregulation, yellow -- upregulation). The waffle graph dots reflect the regulation dynamic following transplantation (similar to the scheme arrows) **(B)** IPA-generated top canonical pathways with predicted regulation (*z*-score ≥ 1.8) characterizing the protein subset exhibiting islet-promoting regulation. **(C)** Top predicted activated upstream transcription regulators and graph depicting the number of relevant target DEPs in the HNF1A, HNF4A and FOXO3 network following a regulation toward islet abundance levels. **(D)** IPA generated hierarchical clustering of the predicted disease and function processes for the conditions compared. **(E)** Selected signature-relevant DEPs exhibiting regulation toward islet abundance levels. **(F)** Selected top 5 organic network linking MECP2, lipid and energy metabolism. Abbreviations: DEPs, differentially expressed proteins; FC, fold change; S5, stage 5 cells (pancreatic progenitor stage); 2w_postTX, 2 weeks following transplantation (differentiation in mice), Path, pathway; ROS, reactive oxygen species). For abbreviations see [Supplementary Table S3](#TS3){ref-type="supplementary-material"}.](fcell-08-00109-g003){#F3}

The pathway analysis of the protein subset exhibiting islet-promoting regulation revealed that the proteins defining the energy metabolism signature detected above are encompassed in this group ([Figure 3B](#F3){ref-type="fig"} and [Supplementary Figure S2F](#SM1){ref-type="supplementary-material"}). This suggests that transplantation improves the energetic status of the cells toward the one presented by native islets. The evaluation of the observed regulatory landscape pointed once again to HNF1A as top activated upstream regulator ([Supplementary Figure S2G](#SM1){ref-type="supplementary-material"}), while RICTOR (Rapamycin-insensitive companion of mTOR) was predicted as top inhibited ([Supplementary Figure S2H](#SM1){ref-type="supplementary-material"}). In addition, the activation of transcription factors with function in islet development and growth, such as HNF4A or FOXO3, was reiterated in this context, suggesting that the protein signatures defined by these regulators contribute to the acquisition of an islet-like phenotype. Indeed, the vast majority of the proteins compatible with HNF1A (94.44%), HNF4A (68.75%) and FOXO3 (69.23%) regulation responded to the *in vivo* effect by following an islet-promoting regulation ([Figure 3C](#F3){ref-type="fig"} and [Supplementary Figure S2I](#SM1){ref-type="supplementary-material"}).

Correspondingly, the comparative overall disease and function analysis inferred the signature of oxidative stress inhibition to be orchestrated by proteins displaying an islet-promoting regulation in response to the *in vivo* environment ([Figure 3D](#F3){ref-type="fig"}, red cassette). Moreover, an active glycolysis and oxygen consumption was also predicted based on the proteins belonging to this subset, strengthening the assertion of an improved energetic and metabolic status of the cells following transplantation ([Figure 3D](#F3){ref-type="fig"}, yellow cassette). In contrast, the neurogenesis/neuritogenesis signature identified in the overall *in vivo* effect was not detected in the islet-promoting subset ([Figure 3D](#F3){ref-type="fig"}, blue cassette), indicating that the proteins characterizing this signature do not contribute directly to the acquisition of an islet-like cell fate, rather fulfill a maintenance role required for the graft adaptation and survival in the transplantation niche.

Of note, Neuroendocrine convertase 1 (PCSK1, +24.30×, *p* = 0.0002) and 2 (PCSK2, +7.31×, *p* = 0.0073) the key neuroendocrine convertases responsible for insulin, glucagon and somatostatin processing were amongst the significantly upregulated proteins displaying a sustained islet-promoting regulation toward values presented in native islets. Similarly, the levels of SOD1 (superoxide dismutase 1, +2.372× *p* = 0.0177) and SOD2 (superoxide dismutase 2, +2.068×, *p* = 0.0074), essential for destructing superoxide radicals and maintaining the cell redox balance, displayed improved abundance levels, closer to the ones detected in human islets. Finally, proteins involved in synthesis of reactive oxygen species, such as PIN1 (Peptidyl-prolyl *cis-trans* isomerase NIMA-interacting 1, −5.08×, *p* = 0.0007) and PXDN (Peroxidasin homolog, −6.05×, *p* = 0.0430) presented a steep decrease toward islet abundance levels following transplantation ([Figure 3E](#F3){ref-type="fig"}).

Overall, these results suggest an improvement of the redox balance, glucose and energy metabolism in the transplanted cells in response to *in vivo* exposure. In contrast, other processes stimulated by the *in vivo* niche, such as neuritogenesis, do not follow a trend compatible to the islet cell fate acquisition, although they might, however, have an essential role in the graft survival.

Improved Energy Metabolism Status Is Linked to Enhanced Expression of Epigenetic Modifiers Involved in Cell Fate Restriction {#S3.SS6}
----------------------------------------------------------------------------------------------------------------------------

To investigate if the improved energetic signature could be related to the observed improvement of cell fate selection in the transplanted cells, we performed network analysis on the protein subset exhibiting islet-promoting regulation with a focus on modulated epigenetic modifiers. We identified in the dataset four DEPs with known epigenetic role ([Supplementary Figure S2J](#SM1){ref-type="supplementary-material"}). Further inquiry revealed the upregulation of MECP2 (Methyl-CpG-binding protein 2, 1.74×, *p* = 0.0458) in the *in vivo* exposed cells, a key enzyme involved in maintaining the repression of α-cell fate in β-cells ([@B15]). This enzyme acts by binding the methylated locus of the essential α-cell determinant gene, *ARX* (Aristaless-related homeobox), in β-cells, thus preventing its expression in the insulin producing cells. Previous studies demonstrated the importance of MECP2 for restricting hormone selection as its loss results in misexpression of key α-cell markers such as MAFB (V-maf musculoaponeurotic fibrosarcoma oncogene homolog) or glucagon in murine β-cells. Consequently, the detected improved expression of this enzyme is consistent with the observed decrease of the bihormonal fraction. Unfortunately, due to inherent sensitivity issues related to performing proteomics on encapsulated samples, we were unable to confirm ARX or MAFB decrease as a consequence of MECP2 activation in the transplanted cells. Of note, as MAFB retains its expression in mature human β-cells ([@B12]; [@B13]), it is possible that its regulation is not affected in the human context. Interestingly, MECP2 was organically networked with regulated proteins involved in the lipid and energy metabolism ([Figure 3F](#F3){ref-type="fig"}), suggesting a link between the improved energetic status of the transplanted cells and its upregulation.

The *in vivo* Exposure Effect on Cell Fate Restriction Is Mediated by HNF1A and HNF4A Induction {#S3.SS7}
-----------------------------------------------------------------------------------------------

Since the above analyses predicted a central role for HNF1A for the observed proteome landscape response to *in vivo* exposure, we focused on validating its role in islet cell fate decisions following transplantation. As to our knowledge there are no available pharmacological agents for modulating HNF1A activity, we employed hiPSC cells derived from Norwegian patients bearing a dominant heterozygous mutation (hot-spot mutation P291fsinsC) in the *HNF1A* ([@B4]).

We first differentiated *HNF1*α^Δ/+^ hiPSC toward S5-cells, followed by encapsulation and xenotransplantation ([Figure 4A](#F4){ref-type="fig"}). Of note, a bulk global proteomics comparison of standard Matrigel-differentiated *HNF1*α^Δ/+^ (S7_HNF1α^Δ/+^) and wild-type cells (S7_WT) revealed a decrease of all islet hormone abundance in the *HNF1*α^Δ/+^ cells, especially somatostatin ([Figure 4B](#F4){ref-type="fig"}). Moreover, the key β-cell marker PDX1 (Pancreas/duodenum homeobox protein 1), the neuroendocrine convertases PCSK1 and PCSK2 as well as the panendocrine marker CHGA exhibited less abundance in the S7_HNF1α^Δ/+^ cells. Interestingly, MAFB, a transcription factor with essential role for both human α- and β-cells displayed increased abundance in the HNF1A deficient samples. As expected, the upstream regulators analysis predicted the inactivation of HNF1A ([Supplementary Figure S2K](#SM1){ref-type="supplementary-material"}). Interestingly, the observed proteome landscape characterizing the *HNF1*α^Δ/+^ cells was also compatible with the inactivation of CDKN2A and HNF4A ([Supplementary Figure S2K](#SM1){ref-type="supplementary-material"}), two upstream regulators inferred above ([Figure 3C](#F3){ref-type="fig"}) as activated in the healthy samples. Furthermore, the proteome signature of the *HNF1*α^Δ/+^ was consistent to the inactivation of PDX1 and PAX6 (Paired box protein Pax-6), critical transcription factors for islet development and cell fate selection ([Supplementary Figure S2K](#SM1){ref-type="supplementary-material"}).

![Assessment of hormone expression patterns in differentiating cells characterized by suboptimal HNF1A or HNF4A levels. **(A)** Experimental workflow. **(B)** Selected islet cell markers regulation in HNF1α^Δ/+^ (pool) following standard *in vitro* differentiation, identified by a pilot global proteomics experiment. **(C)** Confocal imaging of insulin (green), glucagon (red) and DAPI (blue) immunofluorescence staining of encapsulated *HNF1*α^Δ/+^ and WT cells following transplantation. **(D)** Manual counting of the proportion of monohormonal glucagon^+^ cells, monohormonal insulin^+^ cells and bihormonal glucagon^+^insulin^+^ in encapsulated *HNF1*α^Δ/+^ and WT samples before and after *in vivo* exposure (*n* = 7,8,8,7). **(E)** Experimental workflow. **(F)** Confocal imaging of insulin (green), glucagon (red) and DAPI (blue) immunofluorescence staining of encapsulated *HNF1*α^Δ/+^ and WT cells following transplantation. **(G,H)** The proportion of monohormonal glucagon + and monohormonal insulin + cells in *HNF4*α^Δ/+^ and WT samples **(G)** before (*n* = 9,5,9,5) and after **(H)** transplantation (*n* = 26,6,26,6) quantified by Imaris software. **(I)** The fraction of bihormonal glucagon^+^ insulin^+^ cells in HNF4α^Δ/+^ and WT samples after transplantation (*n* = 26,6). **(J)** The fraction of total hormonal^+^ cells in WT, HNF1α^Δ/+^ and HNF4α^Δ/\ +^ samples after transplantation. Scale bars: 100 μm and 50 μm (high magnifications). Graphs data are shown as mean and SD. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 (Mann--Whitney test). Abbreviations: DEPs, differentially expressed proteins; FC, fold change; WT, wild type; D, mutated allele; S5_WT, control stage 5 cells; S5_HNF1α, Stage 5 cells bearing the HNF1α^Δ/*WT*^ mutation; WT_postTX, control cells following transplantation, HNF1α^Δ/*WT*^ \_postTX, HNF1α^Δ/*WT*^ cells after transplant; S5_HNF4α, Stage 5 cells bearing the HNF4α^Δ/*WT*^ mutation; HNF1α^Δ/*WT*^ \_postTX, HNF1α^Δ/*WT*^ cells after transplant.](fcell-08-00109-g004){#F4}

Subsequently, the comparison of HNF1α^Δ/+\_^cells and their WT counterparts after xeno-transplantation did not reveal a significant difference in the fraction of monohormonal glucagon^+^ cells ([Figure 4D](#F4){ref-type="fig"}, first graph). In contrast, the proportion of the monohormonal insulin^+^ cells displayed a steep decline in the transplanted *HNF1*α^Δ/+^ cells ([Figure 4D](#F4){ref-type="fig"}, middle graph). Importantly, the bihormonal fraction decrease observed in the transplanted control was not recapitulated in the HNF1α^Δ/+^-postTX cells ([Figures 4C,D](#F4){ref-type="fig"}, last graph). Of note, the WT and HNF1A^Δ/+^ S7-populations exhibited a similar fraction of insulin^+^NKX6.1^+^ in two independent planar differentiation rounds ([Supplementary Figure S2L](#SM1){ref-type="supplementary-material"}).

These results suggest that *in vivo* exposure promotes the induction of a HNF1A-based mechanism, required for cell fate restriction toward single-hormonal identity possibly by regulating α-cell identity in β-cells.

We further investigated the role of HNF4A induction in mediating the observed *in vivo* effect on cell fate restriction by following the same experimental design as described above ([Figures 4E,F](#F4){ref-type="fig"}). In this case we employed previously generated hiPSCs derived from patients ([@B47]) bearing a dominant heterozygous p.Ile271fs mutation in the coding sequence of the *HNF4A* ([@B53]; [@B18]). Similar to the above rationale, we expect that the *in vivo* effect mediated induction of HNF4A-based mechanisms will be suboptimal following the transplant. Large-scale imaging microscopy revealed no significant change in the fractions of monohormonal glucagon^+^, or monohormonal insulin^+^ cells in *HNF4*α^Δ/+^ condition before xenotransplantation ([Figure 4G](#F4){ref-type="fig"}). In contrast, following exposure to the *in vivo* environment, the percentage of monohormonal insulin^+^ cells was slightly increased in the transplanted *HNF4*α^Δ/+^ samples ([Figure 4H](#F4){ref-type="fig"}). Moreover, the total fraction of bihormonal cells displayed a steep increase as compared to control transplanted cells ([Figures 4F,I](#F4){ref-type="fig"}). These results indicate that HNF4A induction is required for the *in vivo* effect action on cell fate restriction.

Of interest, the fraction of hormone^+^ cells is significantly increased in the HNF4α^Δ/+^\_postTX cells as compared to both the control and HNF1α^Δ/+^\_postTX ([Figure 4J](#F4){ref-type="fig"}). In contrast, in HNF1α^Δ/+^\_postTX the proportion of hormone^+^ cells is lower than in both control and HNF4α^Δ/+^\_postTX. This result advocates a possible role of the *in vivo* effect mediated HNF1A and HNF4A induction on endocrine program commitment.

Taken together these data suggest that the host' *in vivo* effect requires the induction of both HNF1A and HNF4A in order to restrict and control cell fate selection.

Discussion {#S4}
==========

Here we investigated the impact of short-term intraperitoneal xenotransplantation of encapsulated pancreatic progenitors. In this study we report that the brief exposure to the *in vivo* environment is insufficient for boosting the islet cell fraction, yet it is beneficial for cell fate selection as indicated by a steep decrease in the number of bihormonal cells and improved islet proteome signature. Of note, the proportion of bihormonal cells identified in the S7-population was more variable and slightly higher than the one usually reported in the literature (21.81 ± 13.2 vs. 20.2% previously reported in [@B39]. This is probably a repercussion of using planar culturing conditions for the entire length of differentiation. We chose this approach in order to avoid the confounding effect caused by the switch to air-liquid interface (i.e. aggregation) characterizing the last two stages of the original differentiation protocol ([@B39]).

Several works connected the bihormonal phenotype of the *in vitro* differentiated cells to their immaturity status. Consequently, the apparently subtle changes determining the cells to exclusively select and express a single islet hormone represent critical steps toward reaching the functionally mature status previously reported after long-term transplantation experiments ([@B39]). It is tempting to speculate that the rapid initiation of the underlying cell fate restriction program following *in vivo* exposure could indicate an innate defense mechanism protecting against the inclusion of aberrant immature cells in adult host organisms. In addition, it should be stated that the significant islet-profile enhancement following transplantation does not necessarily involve a significant functional improvement. Due to the inherent difficulties in properly assessing the functionality of the encapsulated differentiating cells, this particular parameter requires further investigations. Nevertheless, it is, however, expected that a very brief *in vivo* exposure, such as the one used in this study, will be insufficient to promote any meaningful/detectable improvement in the functionality of the transplanted cells. Indeed, previous studies reported improved functionality and glucose stimulated insulin secretion in similar setups only after about 60 days post xenotransplantation ([@B39]; [@B42]), thus involving longer exposure times.

Moreover, we believe this is the first attempt to comprehensively characterize the effect of the *in vivo* niche on the transplanted cells. On a cautionary note, it should be stated that the demultiplexing performed here is based on the premise that the three effects considered are independent variables. Essentially, it presumes that the encapsulation effect is similar *in vitro* and *in vivo* and thus, the differences between the two contexts are individually prompted by either the differentiation cocktail or the *in vivo* niche. Although this assumption is required for executing the analysis, the possibility that encapsulation effects vary between *in vitro* and *in vivo* environments should be kept in mind. Several previous studies reported increased starvation/hypoxia-based oxidative stress in encapsulated native human islets, as well as aggregated cells ([@B22]; [@B52]; [@B3]; [@B17]), likely due to capsule's size and density of the encapsulated structure. Yet, our analysis indicated that the observed changes in the redox balance are consistent with a more islet-like fingerprint, suggesting that single cells in suspension benefit of improved nutrient and oxygen exposure. In contrast, the proteins defining the neuro/neuritogenesis signature did not display a regulation pattern compatible with islet cell fate acquisition in response to the *in vivo* environment, suggesting the occurrence of additional processes following transplantation. Of interest, a substantial amount of research generated by the transplantation under the kidney capsules of native pancreatic islets/islet cells, reported the rapid vascularization ([@B7]; [@B31]; [@B33]) and innervation of the graft ([@B23], [@B24]). One study showed that the sympathetic reinnervation paralleled the timeline of revascularization, with axons visible inside the islet grafts at 15 days post-transplant, closely associated with blood vessels ([@B41]). Although no study investigated the reinnervation of the encapsulated islets/cells, a similar mechanism might occur following xenotransplantation of encapsulated differentiating cells, possibly initiated by neuritogenic signals generated by the grafted cells.

Furthermore, the upstream regulators analysis predicted the activation of HNF1A transcription factor as top hit responsible for the proteome landscape observed in response *in vivo* environment. Interestingly, HNF1A is a transcriptional regulator with strong bounds with islet cell fate and functionality ([@B54]; [@B51], [@B50]; [@B20]). Of interest, a recent study on genetically modified ESCs via CRISPR/CAS9 system showed that loss of *HNF1A* leads to increased expression of α-cell markers (including glucagon), coupled with decreased expression of β-cells markers such as PAX4 (Paired box protein Pax-4). Furthermore, functional defects in both glycolysis and mitochondrial function were also detected upon *HNF1A* ablation ([@B9]).

Here we show that the *in vivo* niche effect on transplanted cells requires both HNF1A and HNF4A induction. Our data suggest a potential cooperative, however, not overlapping role of the two effect regulators in restricting and maintaining the hormone expression choice. In this specific context, suboptimal HNF1A stimulation coupled with efficient *in vivo* HNF4A induction hinders the effect of *in vivo* niche on both cell identity restriction and, possibly, endocrine program commitment. Correspondingly, suboptimal HNF4A stimulation connected with the efficient *in vivo* HNF1A induction leads to an increased recruitment of endocrine cells characterized by an immature, bihormonal, profile. This interplay indicates that, besides the obvious importance of the optimal HNF1A and HNF4A induction, the ratio between the expression levels is also critical for mediating the *in vivo* effects on islet cell identity. Certainly, establishing HNF1A and HNF4A specific roles in controlling islet cell identity and especially endocrine commitment will require complex future *in vivo/in vitro* investigations into demultiplexing the intricate HNF1A-HNF4A axis. Moreover, the *in vivo* factor/s responsible for their induction are not known. Identification of these signal/s, besides improving the knowledge of the cellular and molecular basis of islet cell identity regulation, might benefit the current differentiation and regeneration strategies.

Based on the above results, we advance a model in which immediately after transplantation the *in vivo* environment promotes the islet profile in the differentiating pancreas progenitor cells, manifested by ameliorating their hormone expression phenotype. This probably occurs via an improved energy metabolism influencing the activity of specific epigenetic modifiers, such as MECP2. The underlying mechanism is at least partially dependent on the optimal levels of HNF1A and HNF4A, as decreased expression of these transcription factors not only cancel the observed confinement toward single hormone expression but also triggers an accumulation of immature bihormonal cells.
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